会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Antibodies and methods for making and using them
    • 用于制造和使用它们的抗体和方法
    • US20080187966A1
    • 2008-08-07
    • US11928201
    • 2007-10-30
    • Laura Simmons
    • Laura Simmons
    • C12N15/09C07K16/00
    • C07K16/22C07K16/00C07K16/42C07K16/4291C07K2317/567
    • The present invention provides methods for producing humanized antibodies and increasing the yield of antibodies and/or antigen binding fragments when produced in cell culture. In one aspect of the invention, at least one framework region amino acid residue of the variable domain is substituted by a corresponding amino acid from a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequence of the variable domain. In another aspect, an amino acid is placed at a position proximal to a cys residue that participates in an intrachain variable domain disulfide bond that corresponds to an amino acid found at that position in a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequence of the variable domain.
    • 本发明提供了当在细胞培养物中产生时产生人源化抗体并增加抗体和/或抗原结合片段的产量的方法。 在本发明的一个方面,可变结构域的至少一个框架区氨基酸残基被来自与HVR1和/或HVR2氨基酸序列具有最高序列同一性的可变结构域共有序列亚组的相应氨基酸取代 可变域。 在另一方面,将氨基酸置于接近cys残基的位置,所述cys残基参与相应于在该位置上发现的氨基酸的可变结构域共有序列亚组中具有最多序列同一性的氨基酸的链内可变结构域二硫键 可变结构域的HVR1和/或HVR2氨基酸序列。
    • 3. 发明授权
    • Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
    • 生产人源化抗体的方法,提高细胞培养中抗体或抗原结合片段的产量
    • US07575893B2
    • 2009-08-18
    • US10764428
    • 2004-01-23
    • Laura Simmons
    • Laura Simmons
    • C12N1/21C12N15/06C12N15/03C12N15/13C07K16/22
    • C07K16/22C07K16/00C07K16/42C07K16/4291C07K2317/567
    • The present invention provides methods for producing humanized antibodies and increasing the yield of antibodies and/or antigen binding fragments when produced in cell culture. In one aspect of the invention, at least one framework region amino acid residue of the variable domain is substituted by a corresponding amino acid from a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequence of the variable domain. In another aspect, an amino acid is placed at a position proximal to a cys residue that participates in an intrachain variable domain disulfide bond that corresponds to an amino acid found at that position in a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequenc of the variable domain.
    • 本发明提供了当在细胞培养物中产生时产生人源化抗体并增加抗体和/或抗原结合片段的产量的方法。 在本发明的一个方面,可变结构域的至少一个框架区氨基酸残基被来自与HVR1和/或HVR2氨基酸序列具有最高序列同一性的可变结构域共有序列亚组的相应氨基酸取代 可变域。 在另一方面,将氨基酸置于接近cys残基的位置,所述cys残基参与相应于在该位置上发现的氨基酸的可变结构域共有序列亚组中具有最多序列同一性的氨基酸的链内可变结构域二硫键 可变结构域的HVR1和/或HVR2氨基酸序列。